Journal of Clinical Virology Publication Demonstrates
Effectiveness and Ease of Use for Routine Testing
AUSTIN, Texas, Nov. 17, 2016 /PRNewswire/ -- Luminex
Corporation (NASDAQ: LMNX) today announced that the internationally
renowned Department of Viroscience at Erasmus Medical Center in
Rotterdam, The Netherlands, has
evaluated the ARIES® System and Flu A/B & RSV CE-IVD Assay for
clinical testing in a recently published study. Erasmus MC is a
consultation center for the World Health Organization on viral
infections, as well as serving as the National Reference Center for
Influenza and Emerging Infections in The
Netherlands.
Photo -
http://photos.prnewswire.com/prnh/20161116/440243
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO
In the study, the ARIES® platform and Flu A/B & RSV Assay
showed a high clinical specificity and sensitivity, comparable to
laboratory developed RT-PCR assays, and better than those of
established assays such as immunochromatographic tests and direct
immunofluorescence assays. Ease of use was found to be comparable
to other rapid molecular test platforms. The ARIES® platform is
unique in that it can also run in-house developed real-time assays
with generic ARIES® cassettes.
"We are proud that after thorough evaluation, ARIES has been
found to be effective and easy to use by one of the world's leading
medical centers for clinical virology," said Thomas Pracht, Managing Director, EMEIA, at
Luminex Corporation. "The Erasmus study demonstrates the quality
and performance of the ARIES® platform and the value of the system
for molecular diagnostic labs that want to perform 'out of sync'
MDx testing — in other words, outside of office hours testing or
stat testing during office hours in between runs. The study also
underlines the importance of 'point of impact' tests, where results
have an immediate impact on patient care and clinical decision
making, even outside normal office hours."
Read the complete study, "Performance evaluation of a rapid
molecular diagnostic, MultiCode based, sample-to-answer assay for
the simultaneous detection of Influenza A, B and respiratory
syncytial viruses," published in the Journal of Clinical Virology,
December 2016, Volume 85,
Pages 65–70.
About Luminex Corporation
At Luminex, our mission is
to empower labs to obtain reliable, timely, and actionable answers,
ultimately advancing health. We offer a wide range of
solutions applicable in diverse markets including clinical
diagnostics, pharmaceutical drug discovery, biomedical research,
genomic and proteomic research, biodefense research, and food
safety. We accelerate reliable answers while simplifying
complexity, and deliver certainty with a seamless experience. To
learn more about Luminex, please visit us at
luminexcorp.com.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements.
Forward-looking statements in this release include statements
regarding the development and testing progress of our pipeline
products, and the regulatory approvals thereof. The words
"believe", "expect", "intend", "anticipates", "confident", "will",
"could", "should", and similar expressions are intended to further
identify such forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995. It is important
to note that the Company's actual results or performance could
differ materially from those anticipated in such forward-looking
statements. Factors that could cause Luminex's actual results or
performance to differ materially include risks and uncertainties
relating to, among others, our ability to launch products on time,
the timing of regulatory approvals, the outcome of clinical trials
as well as the risks discussed under the heading "Risk Factors" in
Luminex's Reports on Forms 10-K and 10-Q, as filed with the
Securities and Exchange Commission. The forward-looking statements
contained herein represent the judgment of Luminex as of the date
of this press release, and Luminex expressly disclaims any intent,
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in Luminex's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Contacts
|
|
Luminex Investor
Contact
|
Luminex Media
Contact
|
Harriss
Currie
|
Christine
Valle
|
Sr. Vice President of
Finance and CFO
|
Sr. Manager, Global
Marketing
|
512.219.8020
|
512.219.8020
|
hcurrie@luminexcorp.com
|
cvalle@luminexcorp.com
|